Singular Genomics Systems, Inc. Stock

Equities

OMIC

US82933R1005

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2024-04-26 EDT 5-day change 1st Jan Change
0.4042 USD +0.90% Intraday chart for Singular Genomics Systems, Inc. +2.33% -12.15%
Sales 2024 * 2.42M 3.31M Sales 2025 * 14.18M 19.39M Capitalization 29.95M 40.93M
Net income 2024 * -87M -119M Net income 2025 * -82M -112M EV / Sales 2024 * 12.1 x
Net cash position 2024 * 788K 1.08M Net Debt 2025 * 25.13M 34.35M EV / Sales 2025 * 3.88 x
P/E ratio 2024 *
-0.35 x
P/E ratio 2025 *
-0.38 x
Employees 255
Yield 2024 *
-
Yield 2025 *
-
Free-Float 81.58%
More Fundamentals * Assessed data
Dynamic Chart
UBS Adjusts Singular Genomics Systems Price Target to $0.50 From $0.40, Maintains Neutral Rating MT
Transcript : Singular Genomics Systems, Inc., Q4 2023 Earnings Call, Mar 18, 2024
Earnings Flash (OMIC) SINGULAR GENOMICS SYSTEMS Posts Q4 Revenue $1.1M, vs. Street Est of $1.04M MT
Singular Genomics Systems, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Singular Genomics Systems, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
North American Morning Briefing : Investors -2- DJ
Transcript : Singular Genomics Systems, Inc. - Special Call
Singular Genomics Systems, Inc. Showcases New G4X? Spatial Sequencer at AGBT and Announces Significant Advances in Throughput, Quality, and Usability for G4 Sequencing Platform CI
Singular Genomics Unveils G4X Spatial Sequencer, Transforming the Landscape of In Situ Multiomic Analysis CI
Goldman Sachs Trims Price Target on Singular Genomics Systems to $0.85 From $0.95, Maintains Neutral Rating MT
Singular Genomics Systems, Inc. Provides Unaudited Revenue Guidance for the Fourth Quarter of 2023 CI
Singular Genomics Systems Expects 31% Growth in Q4 Revenue MT
Transcript : Singular Genomics Systems, Inc., Q3 2023 Earnings Call, Nov 14, 2023
Earnings Flash (OMIC) SINGULAR GENOMICS SYSTEMS Posts Q3 Revenue $0.5M MT
Singular Genomics Systems, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
More news
1 day+0.90%
1 week+2.33%
Current month-21.39%
1 month-21.79%
3 months-14.00%
6 months+21.38%
Current year-12.15%
More quotes
1 week
0.38
Extreme 0.3762
0.43
1 month
0.36
Extreme 0.36
0.52
Current year
0.36
Extreme 0.36
0.66
1 year
0.31
Extreme 0.3101
1.21
3 years
0.31
Extreme 0.3101
33.37
5 years
0.31
Extreme 0.3101
33.37
10 years
0.31
Extreme 0.3101
33.37
More quotes
Managers TitleAgeSince
Founder 55 16-05-31
Chief Executive Officer 39 16-05-31
Director of Finance/CFO 46 19-11-30
Members of the board TitleAgeSince
Founder 82 16-08-31
Director/Board Member 56 17-04-30
Director/Board Member 58 17-03-31
More insiders
Date Price Change Volume
24-04-26 0.4042 +0.90% 106,287
24-04-25 0.4006 -1.67% 18,125
24-04-24 0.4074 -1.69% 34,110
24-04-23 0.4144 +3.60% 77,813
24-04-22 0.4 +1.27% 43,805

Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm

More quotes
Singular Genomics Systems, Inc. is a life science technology company that develops next-generation sequencing (NGS) and multiomics technologies. The Company has developed NGS technology (Sequencing Engine), which is a platform technology for its products. The core of its Sequencing Engine consists of proprietary chemistry, including novel chemical compounds, polymers, and enzymes. Its active product development pipeline consists of two products, each of which is designed to leverage the Sequencing Engine and purpose-built to address different applications. Its first product, the G4 Sequencing Platform (G4), targets the NGS market. Its second product in development, G4X Spatial Sequencer, which leverages its sequencing technology, applying it as an in-situ readout for transcriptomics, proteomics and fluorescent H&E in tissue, with spatial context and on the same platform as the G4. The Company is also engaged in developing PX, which is a development-stage multiomics platform.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.4042 USD
Average target price
0.85 USD
Spread / Average Target
+110.29%
Consensus